Palvella Appoints Former Krystal Biotech Executive to Boost Market Access
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2025
0mins
Should l Buy KRYS?
Krystal Biotech Inc. shares fell 3.30% and hit a 20-day low amid broader market declines, with the Nasdaq-100 down 1.36% and the S&P 500 down 1.06%.
The decline in Krystal Biotech's stock price comes despite the positive news that Palvella Therapeutics has appointed Jennifer J. McDonough, a former executive at Krystal Biotech, as Senior Vice President of Market Access. McDonough's experience in driving VYJUVEK® to significant sales showcases her expertise, which Palvella aims to leverage for its upcoming QTORIN™ rapamycin launch. This strategic appointment highlights the potential for growth in the rare disease market, although it did not prevent the stock's decline.
The implications of this news suggest that while Krystal Biotech is experiencing a downturn, the expertise of its former executive is being recognized in the industry, potentially benefiting Palvella's future endeavors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KRYS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KRYS
Wall Street analysts forecast KRYS stock price to fall
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 246.940
Low
198.00
Averages
229.25
High
278.00
Current: 246.940
Low
198.00
Averages
229.25
High
278.00
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Palvella Appoints New Senior VP of Market Access
- Executive Appointment: Palvella Therapeutics has appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services, leveraging her successful experience at Krystal Biotech to bolster support for the company's QTORIN™ programs.
- Market Access Strategy: During her tenure at Krystal Biotech, McDonough played a pivotal role in driving VYJUVEK® from FDA approval to $389 million in annual sales by 2025, showcasing her deep expertise in the rare disease market.
- Product Launch Preparation: Palvella is gearing up for a potential U.S. launch of QTORIN™ rapamycin, and McDonough's addition will enhance the company's capabilities in payer engagement and patient support, ensuring swift market entry for the product.
- Patient-First Philosophy: McDonough expressed enthusiasm for Palvella's unwavering patient-first approach, committing to ensure that QTORIN™ rapamycin reaches patients quickly and effectively, thereby enhancing the company's market position in the rare disease sector.
See More
Krystal Biotech (KRYS.US) Director Plans to Sell $3.25 Million in Common Stock via Form 144
Stock Sale Announcement: Daniel S. Janney, director of Krystal Biotech (KRYS.US), plans to sell 11,803 shares of the company's common stock on February 27, with an estimated market value of around $3.25 million.
Reduction in Shareholding: Since February 24, 2026, Janney has reduced his shareholding in Krystal Biotech by 60,161 shares, valued at approximately $16.15 million.
See More
Redmile Group Increases Stake in Krystal Biotech
- Share Acquisition: Redmile Group reported an acquisition of 16,317 shares of Krystal Biotech in its SEC filing dated February 17, 2026, with an estimated transaction value of $3.43 million, indicating strong confidence in the company.
- Increased Ownership: Following this purchase, Krystal Biotech now represents 12.3% of Redmile's 13F-reportable AUM, highlighting its significance within the investment portfolio.
- Strong Financial Performance: Krystal Biotech achieved $107.1 million in VYJUVEK revenue for Q4 2025, contributing to total product sales of $389.1 million for the year, with a gross margin of 94%, demonstrating the sustainability of its business model.
- Outstanding Market Performance: The stock price of Krystal Biotech has risen 44% over the past year, significantly outperforming the S&P 500's 13% gain, reflecting market recognition of its future growth potential.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation by $49 Million
- Share Acquisition: Redmile Group disclosed in an SEC filing on February 17, 2026, that it purchased 1,316,390 shares of Scholar Rock Holding Corporation, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, representing 16.9% of the fund's 13F reportable assets, further solidifying its investment position in the biopharmaceutical sector.
- Strong Market Performance: As of February 17, 2026, Scholar Rock's share price stood at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, showcasing market recognition of its growth potential.
- Robust Financial Position: Scholar Rock reported approximately $365 million in cash as of December 31, 2026, projected to sustain operations into 2027, thereby reducing near-term dilution risk and providing confidence for long-term investors.
See More
Stock Market Rebounds Slightly, Nvidia Gains from Meta AI Deal
- Market Rebound: The stock market experienced a slight rebound on Tuesday, despite remaining divided, indicating cautious optimism among investors that could provide some support for future trading.
- Nvidia Gains: Nvidia's stock rose late in the session due to a deal with Meta in the AI sector, reflecting ongoing market confidence in its capabilities, which may drive future earnings growth.
- AMD and Broadcom Decline: In contrast, AMD and Broadcom saw their stock prices slump, suggesting a cautious outlook from the market regarding these companies, which could affect their short-term investment appeal.
- Increased Industry Divergence: The overall market divergence has intensified, with some tech stocks performing well while others face pressure, potentially leading investors to be more selective in their stock choices, impacting overall market liquidity.
See More
Stock Market Rebounds Slightly, Nvidia Gains from Meta AI Deal
- Market Rebound: The stock market experienced a slight rebound on Tuesday, despite remaining divided, indicating cautious optimism among investors that may provide some support for future trading.
- Nvidia Gains: Nvidia's stock rose late in the session due to a deal with Meta in the AI sector, highlighting its ongoing leadership in AI and potential new growth opportunities for the company.
- AMD and Broadcom Decline: In contrast, AMD and Broadcom saw their stock prices slump, reflecting market concerns about the semiconductor industry, which could impact investor confidence and future investment decisions in this sector.
- Divergent Investor Sentiment: While Nvidia performed strongly, the overall market sentiment remains divided, prompting investors to closely monitor industry dynamics and company fundamentals to make more informed investment choices.
See More
Palvella Appoints New Senior VP of Market Access
- Executive Appointment: Palvella Therapeutics has appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services, leveraging her successful experience at Krystal Biotech to bolster support for the company's QTORIN™ programs.
- Market Access Strategy: During her tenure at Krystal Biotech, McDonough played a pivotal role in driving VYJUVEK® from FDA approval to $389 million in annual sales by 2025, showcasing her deep expertise in the rare disease market.
- Product Launch Preparation: Palvella is gearing up for a potential U.S. launch of QTORIN™ rapamycin, and McDonough's addition will enhance the company's capabilities in payer engagement and patient support, ensuring swift market entry for the product.
- Patient-First Philosophy: McDonough expressed enthusiasm for Palvella's unwavering patient-first approach, committing to ensure that QTORIN™ rapamycin reaches patients quickly and effectively, thereby enhancing the company's market position in the rare disease sector.
See More
Krystal Biotech (KRYS.US) Director Plans to Sell $3.25 Million in Common Stock via Form 144
Stock Sale Announcement: Daniel S. Janney, director of Krystal Biotech (KRYS.US), plans to sell 11,803 shares of the company's common stock on February 27, with an estimated market value of around $3.25 million.
Reduction in Shareholding: Since February 24, 2026, Janney has reduced his shareholding in Krystal Biotech by 60,161 shares, valued at approximately $16.15 million.
See More
Redmile Group Increases Stake in Krystal Biotech
- Share Acquisition: Redmile Group reported an acquisition of 16,317 shares of Krystal Biotech in its SEC filing dated February 17, 2026, with an estimated transaction value of $3.43 million, indicating strong confidence in the company.
- Increased Ownership: Following this purchase, Krystal Biotech now represents 12.3% of Redmile's 13F-reportable AUM, highlighting its significance within the investment portfolio.
- Strong Financial Performance: Krystal Biotech achieved $107.1 million in VYJUVEK revenue for Q4 2025, contributing to total product sales of $389.1 million for the year, with a gross margin of 94%, demonstrating the sustainability of its business model.
- Outstanding Market Performance: The stock price of Krystal Biotech has risen 44% over the past year, significantly outperforming the S&P 500's 13% gain, reflecting market recognition of its future growth potential.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation by $49 Million
- Share Acquisition: Redmile Group disclosed in an SEC filing on February 17, 2026, that it purchased 1,316,390 shares of Scholar Rock Holding Corporation, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, representing 16.9% of the fund's 13F reportable assets, further solidifying its investment position in the biopharmaceutical sector.
- Strong Market Performance: As of February 17, 2026, Scholar Rock's share price stood at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, showcasing market recognition of its growth potential.
- Robust Financial Position: Scholar Rock reported approximately $365 million in cash as of December 31, 2026, projected to sustain operations into 2027, thereby reducing near-term dilution risk and providing confidence for long-term investors.
See More
Stock Market Rebounds Slightly, Nvidia Gains from Meta AI Deal
- Market Rebound: The stock market experienced a slight rebound on Tuesday, despite remaining divided, indicating cautious optimism among investors that could provide some support for future trading.
- Nvidia Gains: Nvidia's stock rose late in the session due to a deal with Meta in the AI sector, reflecting ongoing market confidence in its capabilities, which may drive future earnings growth.
- AMD and Broadcom Decline: In contrast, AMD and Broadcom saw their stock prices slump, suggesting a cautious outlook from the market regarding these companies, which could affect their short-term investment appeal.
- Increased Industry Divergence: The overall market divergence has intensified, with some tech stocks performing well while others face pressure, potentially leading investors to be more selective in their stock choices, impacting overall market liquidity.
See More
Stock Market Rebounds Slightly, Nvidia Gains from Meta AI Deal
- Market Rebound: The stock market experienced a slight rebound on Tuesday, despite remaining divided, indicating cautious optimism among investors that may provide some support for future trading.
- Nvidia Gains: Nvidia's stock rose late in the session due to a deal with Meta in the AI sector, highlighting its ongoing leadership in AI and potential new growth opportunities for the company.
- AMD and Broadcom Decline: In contrast, AMD and Broadcom saw their stock prices slump, reflecting market concerns about the semiconductor industry, which could impact investor confidence and future investment decisions in this sector.
- Divergent Investor Sentiment: While Nvidia performed strongly, the overall market sentiment remains divided, prompting investors to closely monitor industry dynamics and company fundamentals to make more informed investment choices.
See More
